SecBot SecBot

CYRX

Cryoport, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. NV· CIK 0001124524 Biotech & Drug Discovery
$19.80 −0.09 (−0.45%)
Nov 16 4:00 PM ET · prev $19.89
Market cap
$1.0B
Small cap
Consensus
Buy
87% Buy or better · 15 analysts
Median target
$21.00
+6% · range $18.00–28.00
1 year
+132.7%
from $8.51 · Nov 17
30 days
+16.6%
from $16.98
52-week range
$7.72–20.74
−5% from high · low Mar 12
Avg volume 20D
1.28M
shares / day
Short interest
3.48M
≈6.9% of shares · +37.3%
Days to cover
4.1
at average volume
Insider net
−$6.2M
0 buyers · 6 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read BULLISH 5 reports · 90 days
Balance 0 bearish · 1 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 4/5

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    6 insiders sold $6.2M.

  • InstitutionsMIXED

    Q3 2026: 20 added (0 new), 15 trimmed or exited.

  • AnalystsBULLISH

    13 of 15 rate it Buy or better. Median target $21.00 (+6%).

  • EstimatesRISING

    Current-quarter EPS estimate −$0.155 → −$0.147 over 90 days.

  • Short sellersBUILDING

    Short interest +37.3% to 3.48M shares. 4.1 days to cover, ≈6.9% of shares.

  • TrendUPTREND

    13% above its 50-day average. New closing high $20.74 on Nov 10.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
Qube Research & Technologies LtdDOUBLED763,033$13.3M
UBS Group AGTRIM490,326$8.5M
PANAGORA ASSET MANAGEMENT INCADD466,029$8.1M
Russell Investments Group, Ltd.DOUBLED399,047$6.9M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPADD140,615$2.4M
JANE STREET GROUP, LLCTRIM138,328$2.4M
SEI INVESTMENTS COADD77,144$1.3M
FRANKLIN TEMPLETON INCTRIM67,679$1.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 87% rate it Buy or better
Strong Buy6Buy7Hold2Sell0Strong Sell0
12-month targets · 9 analysts

Price is inside the target range. Median implies +6%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 6, 2026Keybanc
MAINTAIN
MAINTAINOverweight
Nov 6, 2026Needham
MAINTAIN
MAINTAINBuy
Oct 13, 2026BTIG
MAINTAIN
MAINTAINBuy
Oct 1, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Sep 18, 2026BTIG
REITERATE
REITERATEBuy
Aug 7, 2026Guggenheim
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$6.2M
sold · 6 insiders
DateInsiderTypeValue
Nov 10, 2026
Sawicki Mark W
Chief Scientific Officer
Nov 10, 2026
SELL$199.3K
Nov 9, 2026
HANCOCK DANIEL M
Director
Nov 9, 2026
EXERCISE$291.9K
Nov 9, 2026
HANCOCK DANIEL M
Director
Nov 9, 2026
EXERCISE$301.4K
Nov 9, 2026
HANCOCK DANIEL M
Director
Nov 9, 2026
EXERCISE$143.8K
Nov 9, 2026
HANCOCK DANIEL M
Director
Nov 9, 2026
SELL$1.5M
Aug 11, 2026
SHELTON JERRELL
President, CEO
Aug 11, 2026
SELL$429.4K
Jun 11, 2026
ZECCHINI EDWARD J
Chief Digital and Tech Officer
Jun 11, 2026
EXERCISE$161.3K
Jun 11, 2026
ZECCHINI EDWARD J
Chief Digital and Tech Officer
Jun 11, 2026
SELL$486.2K

Earnings setup

Estimates
−$0.15
EPS estimate, this quarter
+5%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.15-$0.17–-$0.13+5.4%$51.1M
Next Q-$0.17-$0.20–-$0.13+3.8%$52.7M
Current FY-$0.77-$0.88–-$0.70-6.6%$198.1M
Next FY-$0.52-$0.62–-$0.45+10.2%$218.1M

Short side

FINRA· Oct 30, 2026
3,477,459
shares short
+37.3%
vs prior settlement
4.1
days to cover
≈6.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 12, 2026 SEC
Two Cryoport insiders sold shares totaling $1.70M in the week after Q3 earnings beat and raised guidance. Director…
CLUSTER · Impact 4/10
Nov 10, 2026 SEC
Mark W. Sawicki, an officer of Cryoport, filed a Form 144 notice of intent to sell 10,000 shares of common stock, with…
144 · Impact 3/10
Nov 10, 2026 Insider
Sawicki Mark W sold 10,000 shares
Chief Scientific Officer @ $19.93 ($199.3K)
Nov 9, 2026 SEC
Director Daniel M. Hancock filed a Form 144 notice of intent to sell 74,379 shares of Cryoport common stock, valued at…
144 · Impact 2/10
Nov 9, 2026 Insider
HANCOCK DANIEL M acquired via exercise 30,000 shares
Director @ $9.73 ($291.9K)
Nov 9, 2026 Insider
HANCOCK DANIEL M acquired via exercise 23,830 shares
Director @ $12.65 ($301.4K)
Nov 5, 2026 Earnings result
CYRX Q3 2026 Earnings: EPS $-0.25 (-39.0% vs est)
Sep 30, 2026 Inst.
Qube Research & Technologies · DOUBLED
763,033 shares ($13.3M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

10 filings · 2 bullish · 0 bearish · 1 mixed · 7 neutral
All CYRX filing & press-release reports (10)